Advancements in the Treatment of Metastatic Breast Cancer (MBC): The Role of Ixabepilone

Ixabepilone plus capecitabine in advanced breast cancer patients with early relapse after adjuvant anthracyclines and taxanes: A pooled subset analysis of two phase III studies

(2011) Jacek Jassem et al.   BREAST

Breast cancer statistics, 2011

(2011) Carol DeSantis et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study

(2011) Javier Cortes et al.   LANCET

Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer

(2011) Joyce O'Shaughnessy et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase I trial of ixabepilone plus pegylated liposomal doxorubicin in patients with adenocarcinoma of breast or ovary

(2010) E. Chuang et al.   ANNALS OF ONCOLOGY

Efficacy of ixabepilone in ER/PR/HER2-negative (triple-negative) breast cancer

(2010) Edith A. Perez et al.   BREAST CANCER RESEARCH AND TREATMENT

Randomized Phase III Trial of Ixabepilone Plus Capecitabine Versus Capecitabine in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane

(2010) Joseph A. Sparano et al.   JOURNAL OF CLINICAL ONCOLOGY

Human Microtubule-Associated-Protein Tau Regulates the Number of Protofilaments in Microtubules: A Synchrotron X-Ray Scattering Study

(2009) M.C. Choi et al.   BIOPHYSICAL JOURNAL

A phase II trial of trastuzumab plus weekly ixabepilone and carboplatin in patients with HER2-positive metastatic breast cancer: an Eastern Cooperative Oncology Group Trial

(2009) Stacy Moulder et al.   BREAST CANCER RESEARCH AND TREATMENT

Defective Repair of Oxidative DNA Damage in Triple-Negative Breast Cancer Confers Sensitivity to Inhibition of Poly(ADP-Ribose) Polymerase

(2009) E. Alli et al.   CANCER RESEARCH

Discovery of Ixabepilone

(2009) J. T. Hunt   MOLECULAR CANCER THERAPEUTICS

Metastatic Breast Cancer: Therapeutic Options According to Molecular Subtypes and Prior Adjuvant Therapy

(2009) V. Guarneri et al.   ONCOLOGIST

Phase I dose escalation study of weekly ixabepilone, an epothilone analog, in patients with advanced solid tumors who have failed standard therapy

(2008) Ahmad Awada et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Preclinical efficacy spectrum and pharmacokinetics of ixabepilone

(2008) Francis Y. F. Lee et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

A Phase I and Pharmacokinetic Study of Ixabepilone in Combination with Carboplatin in Patients with Advanced Solid Malignancies

(2008) R. Plummer et al.   CLINICAL CANCER RESEARCH

Synergistic Antitumor Activity of Ixabepilone (BMS-247550) Plus Bevacizumab in Multiple In vivo Tumor Models

(2008) F. Y.F. Lee et al.   CLINICAL CANCER RESEARCH

Phase II Genomics Study of Ixabepilone as Neoadjuvant Treatment for Breast Cancer

(2008) José Baselga et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical Development of Ixabepilone and Other Epothilones in Patients with Advanced Solid Tumors

(2008) E. Rivera et al.   ONCOLOGIST

Complementary dimerization of microtubule-associated tau protein: Implications for microtubule bundling and tau-mediated pathogenesis

(2008) K. J. Rosenberg et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs

(2008) S. Rottenberg et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA